NEUMORA THERAPEUTICS, INC. (NMRA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -46.27×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -46.27× | Operating income ÷ reported interest expense. $-211.23M ÷ $4.57M ≈ -46.27× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 153.07M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 27.98M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -211.23M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 4.57M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $153.07M | (m) | $27.98M | $-211.23M | $4.57M | (m) | (m) | -46.27× | Reported |
| 2026-03-31 | $162.51M | (m) | $27.96M | $-223.08M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $176.06M | (m) | $29.88M | $-241.16M | $2.01M | (m) | (m) | -119.98× | Reported |
| 2025-09-30 | $177.31M | (m) | $32.37M | $-245.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $197.42M | (m) | $36.34M | $-264.54M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $207.32M | (m) | $41.94M | $-274.33M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $200.93M | (m) | $39.99M | $-263.46M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $193.88M | (m) | $36.14M | $-314.55M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $174.85M | (m) | $32.64M | $-294.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $158.99M | (m) | $22.42M | $-273.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $142.72M | (m) | $17.24M | $-252.10M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $91.75M | (m) | $8.30M | $-135.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |